NCT05560113 Disrupting Fear-based Memory Consolidation
| NCT ID | NCT05560113 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Post-Traumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2022-11-28 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2022-11-28 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinical studies of emotional sensory cortical memory consolidation to reduce the prevalence and negative sequelae of PTSD.
Eligibility Criteria
Inclusion Criteria: * Ability to provide informed consent * Willingness to participate in study * No history of musculoskeletal impairment or neurological disease * Clinical diagnosis of PTSD for individuals in the PTSD group. Exclusion Criteria: * Any participant outside the age range * Participants that show signs of dementia (score \< 20 on the Montreal Cognitive Assessment) * Participants that have a history of major head trauma, a neurodegenerative disorder, or recent (\<6 months) substance abuse; * Participants that had a recent history of Central Nervous System (CNS) active drugs that may influence cortical excitability or learning; or * Participants that report contraindications to TMS or MRI - if participating in the TMS/MRI experiments * Current psychoactive medication usage * Current symptoms of psychosis or bipolar disorder (as indicated by study staff through a clinical interview as part of that study). * The study will exclude adults unable to consent, individuals who are not yet adults, pregnant women and prisoners on scientific grounds and to minimize risk.
Contact & Investigator
Michael Borich, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT05560113 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Post-Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05560113 currently recruiting?
Yes, NCT05560113 is actively recruiting participants. Contact the research team at michael.borich@emory.edu for enrollment information.
Where is the NCT05560113 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT05560113 clinical trial?
NCT05560113 is sponsored by Emory University. The principal investigator is Michael Borich, PhD at Emory University. The trial plans to enroll 66 participants.